Evidence map›Paper›PMID 29963455›Full record

ArticleEuroasian journal of hepato-gastroenterology

Intake of

Tadashi Ohara, Tatsuo Suzutani

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Application and Challenges of Using ProbioticDiseases (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Prebiotics: Ignored player in the fight against cancer.Cancer reports (Hoboken, N.J.) · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tadashi OharaDepartment of Intestinal Bioscience and Medicine, Fukushima Medical University, Fukushima City, Fukushima, Japan.
Tatsuo SuzutaniDepartment of Microbiology, Fukushima Medical University, Fukushima City, Fukushima, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe aimed to investigate the effects of intake of yogurt containing MATERIALS AND

methodsThe subjects were 27 healthy persons who were divided into a group taking yogurt containing BB536 (BB536-y group; n = 14) and a group taking yogurt containing BB536 and FOS (BB536-y with FOS group; n = 13) once a day for 5 weeks. The feces were sampled before and after the intake to analyze the amount of SCFA in the feces and the profile of intestinal flora, such as putrefactive bacteria and

resultsIntake of BB536-y increased the total amount of SCFA in the feces and significantly suppressed the detection rate of ETBF and growth of putrefactive bacteria. Intake of BB536-y with FOS was associated with a higher

conclusionThese findings suggest that intake of both BB536-y and BB536-y with FOS prevents colorectal carcinogenesis.

Indexed as

Colorectal carcinomaGastroenterologyIntestinal microbiomePrebioticsProbioticsShort-chain fatty acids.

Identifiers

PMID29963455
PMCPMC6024036
OpenAlexW2806436538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.